Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple supplement boost knee injection results for arthritis sufferers?

NCT ID NCT07680101

Symptom relief Sponsor: Universita di Verona Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests whether adding an oral supplement (PEA) to a series of knee injections (adelmidrol and hyaluronic acid) can better reduce pain and improve function in people with knee arthritis. The injections aim to protect the joint from damage, while the supplement may help calm nerve-related inflammation. The trial involves 80 adults with knee osteoarthritis or rheumatoid arthritis who will receive either the injections alone or the injections plus the oral supplement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adelmidrol 2% / Hyaluronic Acid 1% (injection) and micronized/ultramicronized Palmitoylethanolamide (oral supplement)
What this could lead to
If successful, this combination could offer a new way to ease knee pain and improve mobility for people with osteoarthritis or rheumatoid arthritis.
What could go wrong
This is a small, early-stage study with only 80 participants, so results may not apply to everyone. The supplement may not provide added benefit over the injection alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 40 years * Male or female * Diagnosis of unilateral or bilateral knee joint degeneration due to osteoarthritis or rheumatoid arthritis, Kellgren-Lawrence grade II-III * Duration of knee pain ≥ 6 months * Baseline WOMAC score ≥ 20 * Drug therapy stabilized for at least 3 months in the case of patients with rheumatoid arthritis * Naïve to palmitoylethanolamide treatment * Signed informed consent Exclusion Criteria: * Severe progressive systemic diseases * Contraindications to intra-articular knee injections * Intra-articular knee injections within 3 months prior to enrollment * Knee surgery within 6 months prior to enrollment * Systemic treatment with chondroprotectors within 1 month prior to enrollment * Systemic corticosteroid treatment within 1 month prior to enrollment * Chronic Non-Steroidal Anti-Inflammatory Drugs (NSAID) therapy * Pregnancy or breastfeeding * Known hypersensitivity to study treatments

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Degenerative joint disease of knee are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neuroinflammatory Diseases osteoarthritis susceptibility 6 osteoarthritis, knee rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Degenerative joint disease of knee Rheumatoid arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.